PDS Biotechnology (NASDAQ: PDSB) expects to report preliminary data in the first or second quarter of 2021 from a collaboration with the NCI, evaluating its lead oncology product, PDS0101, for the treatment of advanced...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Raymond James ups Protech Home Medical PT to $3 (Canadian) from $2.00
Raymond James raised its price target for Protech Home Medical (TSXV:PTQ) to $3 (Canadian) from $2.00, citing an update to its valuation methodology. The stock closed at $2.05 on Jan. 21. Protech is a provider of...
Cantor Fitzgerald starts iBio at OW; PT $3
Cantor Fitzgerald launched coverage of iBio (NYSE American:IBIO) with an “overweight” rating and price target of $3. The stock closed at $1.46 on Jan. 21. iBio focuses on plant-made biologics manufacturing, which is...
BTIG cuts Senseonics to neutral from buy; removes PT
BTIG downgraded Senseonics Holdings (NYSE American:SENS) to “neutral” from “buy” and removed its price target, citing Senseonics’ stock price, which has soared about 500% over the past month. The stock closed at $2.67...
Think Research to acquire MDBriefCase Group
Think Research (TSXV:THNK) agreed to acquire closely-held MDBriefCase Group, a portfolio company of Persistence Capital Partners, for $25.3-million, mostly in stock. The transaction, which is expected to close in the...
Jim Lilly joins England & Co. in healthcare investment banking
Jim Lilly joined England & Co., a middle-market investment bank, as a managing director in its New York office. Mr. Lilly brings more than 30 years of experience as a strategic advisor to a wide variety of...
Canaccord ups Neuronetics PT to $20 from $8
Canaccord Genuity raised its price target for Neuronetics (NASDAQ:STIM) to $20 from $8, reflecting the company’s strong fourth quarter preliminary financial results and a new focus on high-margin utilization, compared...
HCW ups XOMA PT to $56 from $30
H.C. Wainwright raised its price target for XOMA (NASDAQ:XOMA) to $56 from $30, citing the company’s growing asset base, which is linked to both increasing levels of milestone payments and future royalty potential from...
Sernova’s Cell Pouch shows sustained clinical benefit in Type 1 diabetes
Sernova (TSXV:SVA; OTC:SEOVF; FSE:PSH) reported additional positive preliminary safety and efficacy data for its Cell Pouch transplanted with insulin producing cells in patients with Type 1 diabetes. Data presented at...
Justin Zelin joins BTIG as biotech analyst
BTIG has expanded its healthcare research coverage, adding Justin Zelin to its research and strategy division as a director. His biotech research coverage will include cell therapy, targeted oncology, immunology and...
SVB Leerink ups NextGen Healthcare PT to $21 from $14
SVB Leerink raised its price target for NextGen Healthcare (NASDAQ:NXGN) to $21 from $14, citing unaudited preliminary fiscal third quarter results ended Dec. 31, 2020 that beat Street estimates and higher fiscal 2021...
Neuronetics Q4 preliminary revenue tops guidance
Neuronetics (NASDAQ:STIM) reported preliminary unaudited revenue for the fourth quarter of 2020 between $15-million and $15.5-million, compared with previous guidance of $13-million and $13.5-million. “During the...
IntelGenx names Tommy Kenny as VP of intellectual property and legal affairs, general counsel
IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) appointed Tommy Kenny as VP intellectual property and legal affairs, general counsel of IntelGenx Corp., the company’s operating subsidiary. Mr. Kenny has been with...
Just a few of the companies we’ve highlighted along the way
